(NP (NP Severe/JJ 5-fluorouracil/NN toxicity/NN) (ADJP secondary/JJ (PP to/TO (NP dihydropyrimidine/NN dehydrogenase/NN deficiency/NN))) ./.)
(NP (NP A/DT (ADJP potentially/RB more/RBR common/JJ) pharmacogenetic/JJ syndrome/NN) ./.)
(S (NP-SBJ This/DT study/NN) (VP describes/VBZ (NP (NP-COOD (NP (NP the/DT inheritance/NN) (PP of/IN (NP (NP a/DT defect/NN) (PP in/IN (NP pyrimidine/NN catabolism/NN))))) and/CC (NP (NP its/PRP$ association/NN) (PP with/IN (NP drug-induced/JJ toxicity/NN)))) (PP in/IN (NP (NP a/DT patient/NN) (VP receiving/VBG (NP 5-fluorouracil/NN (PRN -LRB-/-LRB- (NP FUra/NN) -RRB-/-RRB-)) (PP as/IN (NP (NP adjuvant/JJ chemotherapy/NN) (PP for/IN (NP breast/NN carcinoma/NN))))))))) ./.)
(S (NP-SBJ The/DT study/NN population/NN) (VP included/VBD (NP-COOD (NP (NP (NP the/DT affected/VBN patient/NN) (PRN -LRB-/-LRB- (NP proband/NN) -RRB-/-RRB-)) ,/, (NP (NP nine/CD) (PP of/IN (NP her/PRP$ blood/NN relatives/NNS))) ,/,) and/CC (NP seven/CD healthy/JJ volunteers/NNS))) ./.)
(S (NP-SBJ-30 (NP The/DT activity/NN) (PP of/IN (NP (NP (NP (NP dihydropyrimidine/NN dehydrogenase/NN) (PRN -LRB-/-LRB- (NP DPD/NN) -RRB-/-RRB-)) ,/, (NP (NP the/DT initial/JJ enzyme/NN) (PP of/IN (NP (NP-COOD (NP pyrimidine/NN) -LRB-/-LRB- and/CC (NP FUra/NN) -RRB-/-RRB-) catabolism/NN))) ,/,) (PP in/IN (NP peripheral/JJ blood/NN mononuclear/JJ cells/NNS))))) (VP was/VBD (VP measured/VBN (NP *-30/-NONE-) (PP in/IN (NP each/DT subject/NN)) (PP by/IN (NP (NP a/DT specific/JJ radiometric/JJ assay/NN) (VP using/VBG (NP FUra/NN) (PP as/IN (NP the/DT substrate/NN))))))) ./.)
(S (NP-SBJ The/DT proband/NN) (VP had/VBD (NP no/DT detectable/JJ DPD/NN activity/NN)) ./.)
(S (SBAR-TMP (WHADVP-101 When/WRB) (S (NP-SBJ-31 (NP enzyme/NN levels/NNS) (PP in/IN (NP the/DT (NP-COOD (NP proband/NN) and/CC (NP relatives/NNS))))) (VP were/VBD (VP compared/VBN (NP *-31/-NONE-) (PP with/IN (NP (NP that/DT) (PP in/IN (NP controls/NNS)))) (ADVP *T*-101/-NONE-))))) ,/, (NP-SBJ-32 (NP an/DT autosomal/JJ recessive/JJ pattern/NN) (PP of/IN (NP inheritance/NN))) (VP was/VBD (VP demonstrated/VBN (NP *-32/-NONE-))) ./.)
(S (NP-SBJ This/DT) (VP is/VBZ (NP-PRD-COOD (NP (NP the/DT third/JJ patient/NN) (PP with/IN (NP (NP severe/JJ FUra/NN toxicity/NN) (ADJP secondary/JJ (PP to/TO (NP (NP an/DT alteration/NN) (PP in/IN (NP pyrimidine/NN catabolism/NN)))))))) and/CC (NP (NP the/DT second/NN) (PP from/IN (NP our/PRP$ clinic/NN population/NN)))) (S (NP-SBJ */-NONE-) (VP suggesting/VBG (SBAR that/IN (S (NP-SBJ (NP the/DT frequency/NN) (PP of/IN (NP this/DT genetic/JJ defect/NN))) (VP may/MD (VP be/VB (ADJP-PRD (ADJP greater/JJR) (SBAR than/IN (S (NP-SBJ-33 */-NONE-) (ADVP-TMP previously/RB) (VP thought/VBN (NP *-33/-NONE-)))))))))))) ./.)
(S (S-SBJ (NP-SBJ */-NONE-) (VP Monitoring/VBG (NP DPD/NN activity/NN))) (VP may/MD (VP be/VB (ADJP-PRD important/JJ) (PP in/IN (NP (NP the/DT management/NN) (PP of/IN (NP (NP patients/NNS) (VP experiencing/VBG (NP (NP severe/JJ toxicity/NN) (ADJP secondary/JJ (PP to/TO (NP FUra/NN chemotherapy/NN))))))))))) ./.)
